Clinical trials: Mild to Moderate Hypertension
Mild to Moderate Hypertension and Elevated Low-Density Lipoprotein Cholesterol
A Study of BEBT-701 in Patients With Mild to Moderate Hypertension and Elevated Low-Density Lipoprotein Cholesterol（LDL-C）
This Phase I/II clinical trial is designed to evaluate, through a single-dose Phase I segment and a multiple-dose Phase II segment, the safety/tolerability, pharmacokinetic (PK) profile, and pharmacodynamic (PD) characteristics…
- Trial name
- NCT07368608
- Testing
- BEBT-701 Injection
- Where
- China
- Volunteers
- 340 people
- Sponsor
- BeBetter Med Inc
Mild to Moderate Hypertension
Phase II Clinical Study of HRS-9563 in Patients With Mild to Moderate Hypertension
This study aims to evaluate the efficacy and safety of HRS-9563 in patients with mild to moderate hypertension, and to explore its appropriate dosage.
- Trial name
- NCT07297797
- Testing
- HRS-9563 Injection, sodium chloride injection
- Where
- China
- Volunteers
- 238 people
- Sponsor
- Fujian Shengdi Pharmaceutical Co., Ltd.
Mild to Moderate Hypertension
A Study to Evaluate Zilebesiran in Japanese Patients With Mild to Moderate Hypertension
The purpose of this study is to evaluate the safety, tolerability, efficacy, pharmacodynamics (PD) and pharmacokinetics (PK) of zilebesiran in Japanese patients with mild to moderate hypertension.
- Trial name
- NCT06423352
- Testing
- Zilebesiran
- Where
- 3 sites in Japan
- Volunteers
- 36 people
- Sponsor
- Alnylam Pharmaceuticals
Mild-to-moderate Essential Hypertension
A Phase III Clinical Trial Evaluating the Efficacy and Safety of Valsartan/Levamlodipine (SYH9056) Tablets In Hypertensive Patients
SYH9056 tablets are a combination of valsartan and levamlodipine maleate. This is a multicenter, randomized, double-blind, parallel-controlled phase III study, designed to validate the efficacy and safety of SYH9056 tablets in…
- Trial name
- NCT06771245
- Testing
- SYH9056, Levamlodipine, Valsartan
- Volunteers
- 606 people
- Sponsor
- CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
Primary Mild and Moderate Hypertension
Study on Human Mass Balance of SPH3127 Tablets
To quantitatively analyze the total radioactivity in the excreta of healthy male subjects after oral administration of [14C] SPH3127, and determine the cumulative excretion rate and main excretion routes of radioactive…
- Trial name
- NCT05593562
- Testing
- SPH3127
- Where
- China
- Volunteers
- 6 people, healthy volunteers welcome
- Sponsor
- Shanghai Pharmaceuticals Holding Co., Ltd
Essential Hypertension ( Mild to Moderate)
Efficacy and Tolerability of an Aliskiren-based Treatment Algorithm in Patients With Mild to Moderate Hypertension
This study will assess the efficacy of an aliskiren based treatment regimen in reaching blood pressure (BP) target in patients with mild to moderate hypertension.
- Trial name
- NCT00765947
- Testing
- Aliskiren, Hydrochlorothiazide, Amlodipine
- Where
- 4 sites in France, Hungary and 2 more
- Volunteers
- 256 people
- Sponsor
- Novartis
Mild to Moderate Hypertension
Evaluation of Drug-drug Interaction Between LCZ696 and Sildenafil in Subjects With Mild to Moderate Hypertension
This study was conducted to investigate the potential for a pharmacokinetic drug-drug interaction in support of the co-administration of LCZ696 and sildenafil.
- Trial name
- NCT01601470
- Testing
- LCZ696, Sildenafil
- Where
- Germany
- Volunteers
- 28 people
- Sponsor
- Novartis Pharmaceuticals
Mild Essential Hypertension, Moderate Essential Hypertension
Safety, Tolerability and Efficacy of a Vaccine Against Essential Hypertension
The study medication CYT006-AngQb is a vaccine, consisting of angiotensin II (Ang II), the naturally occurring octapeptide coupled onto the surface of virus-like particles (VLP).
- Trial name
- NCT00710372
- Testing
- CYT006-AngQb
- Where
- Switzerland
- Volunteers
- 83 people
- Sponsor
- Cytos Biotechnology AG